The Significant Role of Proteomics in Drug Development and Precision Medicine

 The Significant Role of Proteomics in Drug Development and Precision Medicine

by Gary Kruppa, Vice President of Proteomics at Bruker Daltonics, and Roman Fischer, Associate Professor in Clinical Proteomics, Target Discovery Institute, University of Oxford

The proteomics market is expected to grow 16.6% by 2026.1 Significant advances in technology and new methodologies over the last two decades have made proteomics an extremely powerful tool for protein scientists, biologists, and clinical researchers.2 The discovery of diagnostic and prognostic markers are the driving force behind finding new cures for diseases.

Mass spectrometry (MS) can help researchers to discover critical “molecular windows” within complex disease processes. The ongoing developments in MS technology have enabled researchers to start visualizing the proteome – the set of proteins expressed at a particular time – of a cell or organism, with the goal of comprehensively identifying all proteins and their associated biological activities. This article will discuss the accelerated use of proteomics in biomedical and clinical research laboratories, as well as research at Oxford University’s Target Discovery Institute (TDI) and the work the team has undertaken in response to the COVID-19 pandemic.

Read more on Labcompare.